Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

LiquidThetaLEAPS Oct. 25 at 5:44 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $VSTM Current Share Price: $7.95 Contracts: $VSTM January 15, 2027 $10 Calls Scale in: $3.53- $4.32 Scale out: $5.49-$7.06 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com

0 · Reply

dl42 Oct. 25 at 3:22 PM

$VSTM maybe it’s just me being optimistic but this reminds me of TGTX 3-4yrs ago. It just hung around below $10 even w a bunch of upcoming catalysts and then they all started to hit.

0 · Reply

Universaal Oct. 25 at 2:15 AM

$VSTM we get another opportunity to load more under 7.90

0 · Reply

NIJO89 Oct. 24 at 11:36 PM

$VSTM Verastem Oncology (VSTM) - Q3 2025 Overview and Key Upcoming Q4 Catalysts: The second-quarter Form 10-Q (filed August 7, 2025) outlined multiple milestones expected in the second half of 2025. While Q3 will primarily reflect early U.S. launch revenue from AVMAPKI (avutometinib + defactinib), expected to land around US $6–8 million, and steady progress in the VS-7375 KRAS G12D program, four major updates remain pending for Q4 2025 that could significantly influence both sentiment and valuation.

0 · Reply

Sdcharger Oct. 24 at 8:12 PM

$VSTM Short interest at: 10/15. 18.1 million 9/30. 17.5 million The shorts continue to press their bets and the stock continues to lag.

1 · Reply

Marketismanipulated2 Oct. 24 at 8:06 PM

$VSTM special place in hell for these thieving clock suckers!🤬🤬🤬

0 · Reply

SagehenNed Oct. 24 at 7:48 PM

$VSTM classic late day VSTM fade.

1 · Reply

Marketismanipulated2 Oct. 24 at 7:33 PM

$VSTM thieves let it run up or down into the close? Guessing down since they have zero morals.

0 · Reply

Universaal Oct. 24 at 4:54 PM

$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both

0 · Reply

Universaal Oct. 24 at 4:14 PM

$VSTM all I request Dan not to dilute anymore just get some investments from big biotech companies or cut your fking salaries

0 · Reply

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 2 days ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 6 days ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 7, 2025, 7:30 AM EDT - 18 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Aug 13, 2025, 4:29 PM EDT - 2 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 2 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 3 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 3 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 4 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 4 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 4 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 5 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 5 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 5 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 5 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 5 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 6 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 6 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 6 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 7 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 7 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 7 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 8 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 9 months ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 10 months ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 10 months ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 10 months ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 10 months ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 10 months ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 10 months ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 10 months ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 11 months ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 11 months ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 11 months ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Participate in Upcoming Investor Conferences

Oct 17, 2024, 1:00 AM EDT - 1 year ago

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

Oct 9, 2024, 6:00 AM EDT - 1 year ago

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting

Sep 5, 2024, 11:21 PM EDT - 1 year ago

Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates

LiquidThetaLEAPS Oct. 25 at 5:44 PM

0 · Reply

dl42 Oct. 25 at 3:22 PM

$VSTM maybe it’s just me being optimistic but this reminds me of TGTX 3-4yrs ago. It just hung around below $10 even w a bunch of upcoming catalysts and then they all started to hit.

0 · Reply

Universaal Oct. 25 at 2:15 AM

$VSTM we get another opportunity to load more under 7.90

0 · Reply

NIJO89 Oct. 24 at 11:36 PM

0 · Reply

Sdcharger Oct. 24 at 8:12 PM

$VSTM Short interest at: 10/15. 18.1 million 9/30. 17.5 million The shorts continue to press their bets and the stock continues to lag.

1 · Reply

Marketismanipulated2 Oct. 24 at 8:06 PM

$VSTM special place in hell for these thieving clock suckers!🤬🤬🤬

0 · Reply

SagehenNed Oct. 24 at 7:48 PM

$VSTM classic late day VSTM fade.

1 · Reply

Marketismanipulated2 Oct. 24 at 7:33 PM

$VSTM thieves let it run up or down into the close? Guessing down since they have zero morals.

0 · Reply

Universaal Oct. 24 at 4:54 PM

$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both

0 · Reply

Universaal Oct. 24 at 4:14 PM

$VSTM all I request Dan not to dilute anymore just get some investments from big biotech companies or cut your fking salaries

0 · Reply

MrWaikoloa Oct. 24 at 3:57 PM

$VSTM Heating up niy. Wouldn’t surprise me to see 9 today.

1 · Reply

Universaal Oct. 24 at 3:47 PM

$VSTM 😃🤣🤣

0 · Reply

sweddle Oct. 24 at 3:45 PM

$VSTM

0 · Reply

Universaal Oct. 24 at 3:09 PM

$VSTM added 11k more shares at 7.87, 26k shares holding give me $10 I will get out

1 · Reply

Universaal Oct. 24 at 3:02 PM

$VSTM a fkr finally bought 48k shares at 7.78

0 · Reply

PencilNeckGeek Oct. 24 at 2:44 PM

$VSTM Volume so low one small hedge fund can completely take this wherever they want it to go

1 · Reply

Marketismanipulated2 Oct. 24 at 2:26 PM

$VSTM shop this company around to highest bidder for crying out loud for the sake of your shareholders.

0 · Reply

PencilNeckGeek Oct. 24 at 2:22 PM

$VSTM Well looks like they got it pinned down again for the near future

1 · Reply

Universaal Oct. 24 at 2:13 PM

$VSTM people not convinced buying more here

0 · Reply

Universaal Oct. 24 at 2:02 PM

$VSTM bcz bulls believes these fake people’s comments 😆

0 · Reply

ChesterKaita Oct. 24 at 2:00 PM

$VSTM we cure cancer.. what do you do?

0 · Reply

Universaal Oct. 24 at 1:59 PM

$VSTM it’s not shorts no one shorting it’s just no fresh buying

0 · Reply

Market Cap	480.67M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	2.06

Volume	1,628,600
Avg Vol	2,269,624
Day's Range	N/A - N/A
Shares Out	61.55M
Stochastic %K	33%
Beta	0.89
Analysts	Strong Sell
Price Target	$15.50